Ricky Madison is a pharmaceutical scientist and computational oncologist working at the intersection of drug development, oncology, and artificial intelligence. He has led an independent R&D programme in formulation science and oncology drug discovery for over ten years. Through Medwra, his formulation R&D platform, he has delivered 35+ commercialised softgel products with zero quality failures, supporting 290%+ year-on-year growth in commercial volume.
In oncology discovery, he is the founder of Oncivra, an end-to-end computational discovery platform for the TP53 Y163C cancer mutation, built around the 1.65 Å mutant crystal structure (PDB 8QWL). The platform combines generative molecule design, structure-based pocket discovery, docking, independent Boltz-2 affinity estimation, and ADMET and developability triage, narrowing a 124-molecule campaign to six computationally prioritised candidates for experimental validation. He is also the inventor of Oncyra (Irish patent application S2026/0392), a platform for mutation-aware TP53 structural modelling and drug rescue prediction across thousands of variants, supported by a suite of research applications including the P53 Atlas, Y163C Atlas, DynaPocket, PhenoRescue AI, LNPredict, and MediSynic.
Ricky Madison is a pharmaceutical scientist and computational oncologist working at the intersection of drug development, oncology, and artificial intelligence. He has led an independent R&D programme in formulation science and oncology drug discovery for over ten years. Through Medwra, his formulation R&D platform, he has delivered 35+ commercialised softgel products with zero quality failures, supporting 290%+ year-on-year growth in commercial volume.
In oncology discovery, he is the founder of Oncivra, an end-to-end computational discovery platform for the TP53 Y163C cancer mutation, built around the 1.65 Å mutant crystal structure (PDB 8QWL). The platform combines generative molecule design, structure-based pocket discovery, docking, independent Boltz-2 affinity estimation, and ADMET and developability triage, narrowing a 124-molecule campaign to six computationally prioritised candidates for experimental validation. He is also the inventor of Oncyra (Irish patent application S2026/0392), a platform for mutation-aware TP53 structural modelling and drug rescue prediction across thousands of variants, supported by a suite of research applications including the P53 Atlas, Y163C Atlas, DynaPocket, PhenoRescue AI, LNPredict, and MediSynic.